1. Home
  2. PEPG vs DCTH Comparison

PEPG vs DCTH Comparison

Compare PEPG & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PepGen Inc.

PEPG

PepGen Inc.

HOLD

Current Price

$6.79

Market Cap

317.6M

Sector

Health Care

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$9.12

Market Cap

350.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PEPG
DCTH
Founded
2018
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
317.6M
350.7M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
PEPG
DCTH
Price
$6.79
$9.12
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
4
Target Price
$10.80
$23.00
AVG Volume (30 Days)
780.0K
500.5K
Earning Date
02-26-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
N/A
$79,603,000.00
Revenue This Year
N/A
$132.21
Revenue Next Year
N/A
$33.88
P/E Ratio
N/A
$275.31
Revenue Growth
N/A
251.54
52 Week Low
$0.88
$8.12
52 Week High
$7.80
$18.23

Technical Indicators

Market Signals
Indicator
PEPG
DCTH
Relative Strength Index (RSI) 63.00 39.69
Support Level $4.25 $8.90
Resistance Level $5.46 $10.30
Average True Range (ATR) 0.54 0.51
MACD 0.13 -0.08
Stochastic Oscillator 83.69 14.29

Price Performance

Historical Comparison
PEPG
DCTH

About PEPG PepGen Inc.

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle and the central nervous system. Its pipeline products are; PGN-EDO51, PGN-EDODM1, and others including PGN-EDO53 and PGN-EDO45.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: